We are live on ! Find out more
PALI icon

Palisade Bio
PALI

26 hedge funds and large institutions have $842K invested in Palisade Bio in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

113% more capital invested

Capital invested by funds: $395K → $842K (+$447K)

44% more funds holding

Funds holding: 18 → 26 (+8)

0.01% more ownership

Funds ownership: 0.01% → 0.02% (+0.01%)

Holders
26
Holders Change
+8
Holders Change %
+44.44%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
+$1.59M
2
Renaissance Technologies
Renaissance Technologies
New York
+$135K
3
SM
Sabby Management
Florida
+$126K
4
SIG
Sargent Investment Group
Maryland
+$121K
5
WAM
Warberg Asset Management
Illinois
+$42.3K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$54.8K
2
SWIG
Strategic Wealth Investment Group
Kentucky
-$22K
3
TRCT
Tower Research Capital (TRC)
New York
-$3.39K

PALI Hedge Fund Activity: Q3 2022 in Review

26 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q3 2022, worth a combined $842K — up 113% from $395K a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PALI positions and 1 closed out — a net gain of 8 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Altium Capital Management, opening a new position worth an estimated $1.59M. The largest seller was Vanguard Group, cutting an estimated $54.8K.

  • 26 institutional investors held Palisade Bio (PALI) as of Q3 2022, up from 18 in Q2 2022.
  • Funds reported $842K of Palisade Bio stock for Q3 2022, up 113% quarter-over-quarter.
  • 9 funds opened new Palisade Bio positions in Q3 2022 and 1 closed out, a net change of +8 holders.
  • The largest Palisade Bio buyer in Q3 2022 was Altium Capital Management, an estimated $1.59M added.
  • The largest Palisade Bio seller in Q3 2022 was Vanguard Group, an estimated $54.8K sold.

Based on aggregated 13F filings for Q3 2022.